This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

NCT ID: NCT00731692

Last Updated: 2017-06-14

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 970 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-07-28
• Study Completion Date: 2015-06-22

Brief Summary

The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS. This was an open-label, single-arm extension study to a double-blind, randomized multicenter, placebo-controlled, parallel-group core study. The core study completed and eligible patients enrolled into the extension study at the next scheduled or unscheduled core study visit. All patients, regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension study. The extension study was terminated early after the results of the core study became available showing that the study did not meet its primary endpoint which was defined as confirmed disability progression in this population

Conditions

Primary Progressive Multiple Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

FTY720D 0.5 mg

Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment

Group Type: EXPERIMENTAL

FTY720

Intervention Type: DRUG

Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily

Placebo

Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching placebo capsules were administered orally once daily

FTY720D 1.25 mg switch to 0.5 mg

Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009

Group Type: EXPERIMENTAL

FTY720

Intervention Type: DRUG

Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily

Interventions

FTY720

Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily

Intervention Type: DRUG

Placebo

Matching placebo capsules were administered orally once daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

General

1. sign written informed consent prior to participating in the study

2. 25 through 65 years of age inclusive

3. females of childbearing potential must:

• have a negative pregnancy test at Baseline (prior to randomization) and
• use simultaneously two forms of effective contraception during the treatment and 3-months after discontinuation of study medication

Primary Progressive Multiple sclerosis.

1. diagnosis of primary progressive multiple sclerosis (according to the 2005 Revised McDonald criteria):

2. time since first reported symptoms between 2 and 10 years

3. evidence of clinical disability progression in the 2 years prior to Screening

4. disability status at Screening

• EDSS score of 3.5-6.0 inclusive
• pyramidal functional system score of 2 or more
• 25'TWT less than 30 seconds

• Patients initially randomized to fingolimod 1.25 mg or placebo as part of the first study cohort, were to have completed at least 3 years on study drug treatment at the time of extension study initiation.
• Patients initially randomized to fingolimod 0.5 mg or placebo as part of the second study cohort, were to have continued on study drug treatment until such time as the last ongoing patient enrolled in the study had reached 3 years in study

Exclusion Criteria

PPMS specific:

• History of relapses/attacks
• Progressive neurological disorder other than PPMS
• Pure cerebellar syndrome or pure visual progressive syndrome or pure
• cognitive progressive syndrome
• Presence of spinal cord compression at screening MRI
• Relevant history of vitamin B12 deficit
• Evidence of syphilis or borreliosis at Screening

Cardiovascular conditions:

• Myocardial infarction within the past 6 months or current unstable ischemic heart disease
• History of angina pectoris due to coronary spasm or history of Raynaud's phenomenon
• Severe cardiac failure or cardiac arrest
• History of symptomatic bradycardia
• Resting pulse <55 bpm pre-dose
• History of sick sinus syndrome or sino-atrial heart block
• History or presence of second and third degree AV block or an increase QT interval (QTc>440 ms)
• Arrythmia requiring treatment with class III antiarrythmic drugs
• History of positive tilt test from workout of vasovagal syncope
• Hypertension, not controlled with medication

Pulmonary:

• Severe respiratory disease or pulmonary fibrosis
• TB
• Abnormal X-ray, suggestive of active pulmonary disease
• Abnormal PFT: <70% of predicted for FEV1 and FVC; <60% for DLCO
• Patients receiving chronic (daily) therapies for asthma

Hepatic:

• Known history of alcohol abuse, chronic liver or biliary disease
• Total or conjugated Brb >ULN, unless in context of Gilbert's syndrome
• AP >1.5xULN; ALT/AST >2xULN; GGT>3xULN

Other:

• History of chronic disease of the immune system other than MS
• Malignancy (other than successfully treated SCC or BCC)
• Diabetes Mellitus
• Macular Edema present at screening
• HIV, Hepatitis C or B, other active infection
• History of total lymphoid irradiation or bone marrow transplantation
• Serum creatinine >1.7 mg/dl
• WBC <3500 cells/mm3
• Lymphocyte count <800 cells/mm3
• History of substance abuse or any other factor that may interfere with subject ability to cooperate and comply with the study procedures
• Unable to undergo MRI scans
• Participation in any therapeutical clinical research study in the 6 months prior to randomization
• Pregnant or lactating women
• Drugs requiring wash-out period:

3 months:

• Systemic corticosteroids or ACTH
• INF-beta

6 months:

• Immunosuppressive medication
• Immunoglobulins
• Monoclonal antibodies
• Drugs that exclude participation in the study:
• Cladribine
• Cyclophosphamide
• Mitoxantrone (except: patients who received a cumulative dose of no more than 60mg/m2 more than 5 years ago could enter the study)

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Novartis Investigative Site

Newport Beach, California, United States

Novartis Investigative Site

Sacramento, California, United States

Novartis Investigative Site

Aurora, Colorado, United States

Novartis Investigative Site

Pompano Beach, Florida, United States

Novartis Investigative Site

Tampa, Florida, United States

Novartis Investigative Site

Atlanta, Georgia, United States

Novartis Investigative Site

Chicago, Illinois, United States

Novartis Investigative Site

Chicago, Illinois, United States

Novartis Investigative Site

Kansas City, Kansas, United States

Novartis Investigative Site

Baltimore, Maryland, United States

Novartis Investigative Site

Boston, Massachusetts, United States

Novartis Investigative Site

Brookline, Massachusetts, United States

Novartis Investigative Site

Detroit, Michigan, United States

Novartis Investigative Site

St Louis, Missouri, United States

Novartis Investigative Site

Teaneck, New Jersey, United States

Novartis Investigative Site

Buffalo, New York, United States

Novartis Investigative Site

New York, New York, United States

Novartis Investigative Site

Rochester, New York, United States

Novartis Investigative Site

Stony Brook, New York, United States

Novartis Investigative Site

Charlotte, North Carolina, United States

Novartis Investigative Site

Durham, North Carolina, United States

Novartis Investigative Site

Cleveland, Ohio, United States

Novartis Investigative Site

Columbus, Ohio, United States

Novartis Investigative Site

Pittsburgh, Pennsylvania, United States

Novartis Investigative Site

Knoxville, Tennessee, United States

Novartis Investigative Site

Nashville, Tennessee, United States

Novartis Investigative Site

Dallas, Texas, United States

Novartis Investigative Site

Houston, Texas, United States

Novartis Investigative Site

San Antonio, Texas, United States

Novartis Investigative Site

Burlington, Vermont, United States

Novartis Investigative Site

Charlottesville, Virginia, United States

Novartis Investigative Site

Seattle, Washington, United States

Novartis Investigative Site

Madison, Wisconsin, United States

Novartis Investigative Site

Camperdown, New South Wales, Australia

Novartis Investigative Site

Liverpool, New South Wales, Australia

Novartis Investigative Site

Hobart, Tasmania, Australia

Novartis Investigative Site

Box Hill, Victoria, Australia

Novartis Investigative Site

Heidelberg, Victoria, Australia

Novartis Investigative Site

Parkville, Victoria, Australia

Novartis Investigative Site

Charleroi, , Belgium

Novartis Investigative Site

Edegem, , Belgium

Novartis Investigative Site

Leuven, , Belgium

Novartis Investigative Site

Liège, , Belgium

Novartis Investigative Site

Melsbroek, , Belgium

Novartis Investigative Site

Sint-Truiden, , Belgium

Novartis Investigative Site

Calgary, Alberta, Canada

Novartis Investigative Site

Edmonton, Alberta, Canada

Novartis Investigative Site

Burnaby, British Columbia, Canada

Novartis Investigative Site

Vancouver, British Columbia, Canada

Novartis Investigative Site

Halifax, Nova Scotia, Canada

Novartis Investigative Site

Ottawa, Ontario, Canada

Novartis Investigative Site

Toronto, Ontario, Canada

Novartis Investigative Site

Toronto, Ontario, Canada

Novartis Investigative Site

Gatineau, Quebec, Canada

Novartis Investigative Site

Greenfield Park, Quebec, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Regina, Saskatchewan, Canada

Novartis Investigative Site

Brno, Czech Republic, Czechia

Novartis Investigative Site

Rychnov nad Kněžnou, Czech Republic, Czechia

Novartis Investigative Site

Olomouc, CZE, Czechia

Novartis Investigative Site

Ostrava-Poruba, , Czechia

Novartis Investigative Site

Pilsen, , Czechia

Novartis Investigative Site

Prague, , Czechia

Novartis Investigative Site

Teplice, , Czechia

Novartis Investigative Site

Aarhus, , Denmark

Novartis Investigative Site

Sønderborg, , Denmark

Novartis Investigative Site

Helsinki, , Finland

Novartis Investigative Site

Tampere, , Finland

Novartis Investigative Site

Turku, , Finland

Novartis Investigative Site

Bordeaux, , France

Novartis Investigative Site

Lille, , France

Novartis Investigative Site

Marseille, , France

Novartis Investigative Site

Montpellier, , France

Novartis Investigative Site

Nantes, , France

Novartis Investigative Site

Paris, , France

Novartis Investigative Site

Rennes, , France

Novartis Investigative Site

Strasbourg, , France

Novartis Investigative Site

Berlin, , Germany

Novartis Investigative Site

Berlin, , Germany

Novartis Investigative Site

Bochum, , Germany

Novartis Investigative Site

Dresden, , Germany

Novartis Investigative Site

Düsseldorf, , Germany

Novartis Investigative Site

Erlangen, , Germany

Novartis Investigative Site

Essen, , Germany

Novartis Investigative Site

Freiburg im Breisgau, , Germany

Novartis Investigative Site

Hanover, , Germany

Novartis Investigative Site

Hennigsdorf, , Germany

Novartis Investigative Site

Magdeburg, , Germany

Novartis Investigative Site

München, , Germany

Novartis Investigative Site

München, , Germany

Novartis Investigative Site

Münster, , Germany

Novartis Investigative Site

Teupitz, , Germany

Novartis Investigative Site

Trier, , Germany

Novartis Investigative Site

Würzburg, , Germany

Novartis Investigative Site

Budapest, , Hungary

Novartis Investigative Site

Budapest, , Hungary

Novartis Investigative Site

Debrecen, , Hungary

Novartis Investigative Site

Győr, , Hungary

Novartis Investigative Site

Miskolc, , Hungary

Novartis Investigative Site

Veszprém, , Hungary

Novartis Investigative Site

Bari, BA, Italy

Novartis Investigative Site

Montichiari, BS, Italy

Novartis Investigative Site

Chieti, CH, Italy

Novartis Investigative Site

Catania, CT, Italy

Novartis Investigative Site

Genova, GE, Italy

Novartis Investigative Site

Milan, MI, Italy

Novartis Investigative Site

Milan, MI, Italy

Novartis Investigative Site

Cefalù, PA, Italy

Novartis Investigative Site

Padua, PD, Italy

Novartis Investigative Site

Roma, RM, Italy

Novartis Investigative Site

Roma, RM, Italy

Novartis Investigative Site

Orbassano, TO, Italy

Novartis Investigative Site

Gallarate, VA, Italy

Novartis Investigative Site

Breda, CK, Netherlands

Novartis Investigative Site

Amsterdam, , Netherlands

Novartis Investigative Site

Eindhoven, , Netherlands

Novartis Investigative Site

Nieuwegein, , Netherlands

Novartis Investigative Site

Nijmegen, , Netherlands

Novartis Investigative Site

Sittard-Geleen, , Netherlands

Novartis Investigative Site

Lodz, , Poland

Novartis Investigative Site

Lublin, , Poland

Novartis Investigative Site

Warsaw, , Poland

Novartis Investigative Site

Warsaw, , Poland

Novartis Investigative Site

Seville, Andalusia, Spain

Novartis Investigative Site

Bilbao, Basque Country, Spain

Novartis Investigative Site

Badalona, Catalonia, Spain

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Girona, Catalonia, Spain

Novartis Investigative Site

L'Hospitalet de Llobregat, Catalonia, Spain

Novartis Investigative Site

Lleida, Catalonia, Spain

Novartis Investigative Site

Majadahonda, Madrid, Spain

Novartis Investigative Site

Valencia, Valencia, Spain

Novartis Investigative Site

Madrid, , Spain

Novartis Investigative Site

Madrid, , Spain

Novartis Investigative Site

Gothenburg, , Sweden

Novartis Investigative Site

Stockholm, , Sweden

Novartis Investigative Site

Basel, , Switzerland

Novartis Investigative Site

Bern, , Switzerland

Novartis Investigative Site

Lausanne, , Switzerland

Novartis Investigative Site

Lugano, , Switzerland

Novartis Investigative Site

Zurich, , Switzerland

Novartis Investigative Site

Ankara, , Turkey (Türkiye)

Novartis Investigative Site

Atakum / Samsun, , Turkey (Türkiye)

Novartis Investigative Site

Balcova / Izmir, , Turkey (Türkiye)

Novartis Investigative Site

Istanbul, , Turkey (Türkiye)

Novartis Investigative Site

Yenisehir / Izmir, , Turkey (Türkiye)

Novartis Investigative Site

Salford, Manchester, United Kingdom

Novartis Investigative Site

Sheffield, South Yorkshire, United Kingdom

Novartis Investigative Site

Bristol, , United Kingdom

Novartis Investigative Site

London, , United Kingdom

Novartis Investigative Site

London, , United Kingdom

Novartis Investigative Site

London, , United Kingdom

Novartis Investigative Site

London, , United Kingdom

Novartis Investigative Site

Newcastle upon Tyne, , United Kingdom

Novartis Investigative Site

Norwich, , United Kingdom

Countries

United States; Australia; Belgium; Canada; Czechia; Denmark; Finland; France; Germany; Hungary; Italy; Netherlands; Poland; Spain; Sweden; Switzerland; Turkey (Türkiye); United Kingdom

References

Calvi A, Mendelsohn Z, Hamed W, Chard D, Tur C, Stutters J, MacManus D, Kanber B, Wheeler-Kingshott CAMG, Barkhof F, Prados F. Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis. Eur J Neurol. 2024 Jan;31(1):e16092. doi: 10.1111/ene.16092. Epub 2023 Oct 12.

Reference Type: DERIVED

PMID: 37823722 (View on PubMed)

Leppert D, Kropshofer H, Haring DA, Dahlke F, Patil A, Meinert R, Tomic D, Kappos L, Kuhle J. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Neurology. 2022 May 24;98(21):e2120-e2131. doi: 10.1212/WNL.0000000000200258. Epub 2022 Apr 4.

Reference Type: DERIVED

PMID: 35379762 (View on PubMed)

Koch MW, Mostert J, Repovic P, Bowen JD, Strijbis E, Uitdehaag B, Cutter G. Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. J Neurol. 2022 Mar;269(3):1663-1669. doi: 10.1007/s00415-021-10750-z. Epub 2021 Aug 15.

Reference Type: DERIVED

PMID: 34392376 (View on PubMed)

Koch MW, Mostert J, Zhang Y, Wolinsky JS, Lublin FD, Strijbis E, Cutter G. Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. Neurology. 2021 Sep 28;97(13):e1334-e1342. doi: 10.1212/WNL.0000000000012603. Epub 2021 Aug 10.

Reference Type: DERIVED

PMID: 34376508 (View on PubMed)

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli O, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Haring DA, Wolinsky JS. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

Reference Type: DERIVED

PMID: 29560379 (View on PubMed)

Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Haring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28.

Reference Type: DERIVED

PMID: 26827074 (View on PubMed)

Hartung HP, Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann Neurol. 2009 Oct;66(4):429-32. doi: 10.1002/ana.21880. No abstract available.

Reference Type: DERIVED

PMID: 19847907 (View on PubMed)

Other Identifiers

2007-002627-32

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CFTY720D2306

Identifier Type: -

Identifier Source: org_study_id

NCT01779934

Identifier Type: -

Identifier Source: nct_alias